Abbott
Executive Summary
Agreement to develop and market neurological agent NPS 1776 signed with NPS Pharmaceuticals. NPS 1776 is an alifatic amide with structural similarities to valproic acid (Abbott's Depakote) that may be used to treat bipolar mood disorder and epilepsy. "NPS 1776 has pharmacologically significant structural distinctions that will provide a better safety profile in comparison to valproic acid such as lack of birth defect potential and liver damage," NPS' March 20 SEC filing states. NPS has completed two Phase I safety and tolerability trials on NPS-1776, the company said
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth